Protalix BioTherapeutics, Inc. SEC filings PLX
Protalix BioTherapeutics, Inc. has 972 filings in SEC EDGAR's recent list, going back to Aug 13, 1996. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 12, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| SCHEDULE 13G | Ownership over 5% (passive) | Oct 15, 2026 | — |
| 4 | Insider transaction | Sep 9, 2026 | Sep 3, 2026 |
| 4 | Insider transaction | Sep 4, 2026 | Sep 3, 2026 |
| 4 | Insider transaction | Sep 4, 2026 | Sep 3, 2026 |
| 4 | Insider transaction | Sep 4, 2026 | Sep 3, 2026 |
| 4 | Insider transaction | Sep 4, 2026 | Sep 3, 2026 |
| 4 | Insider transaction | Sep 4, 2026 | Sep 3, 2026 |
| 4 | Insider transaction | Sep 4, 2026 | Sep 3, 2026 |
| 4 | Insider transaction | Sep 4, 2026 | Sep 3, 2026 |
| 4 | Insider transaction | Sep 4, 2026 | Sep 3, 2026 |
| S-8 | Employee stock plan registration | Aug 12, 2026 | — |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Jul 29, 2026 | — |
| 8-K |
Current report
Shareholder vote results
|
Jun 25, 2026 | Jun 25, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
May 21, 2026 | May 21, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 13, 2026 | May 13, 2026 |
| ARS | Annual report to shareholders | Apr 30, 2026 | Dec 31, 2025 |
| DEF 14A | Proxy statement | Apr 30, 2026 | Jun 25, 2026 |
| 3/A | Filing | Apr 27, 2026 | Aug 24, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Mar 30, 2026 | — |
| 10-K | Annual report | Mar 18, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 18, 2026 | Mar 18, 2026 |
| 8-K |
Current report
Other events
|
Mar 9, 2026 | Mar 9, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Mar 4, 2026 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Feb 11, 2026 | Feb 11, 2026 |
| 8-K |
Current report
Other events
|
Jan 30, 2026 | Jan 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 5, 2026 | Jan 5, 2026 |
| 4 | Insider transaction | Dec 23, 2025 | Dec 19, 2025 |
| 4 | Insider transaction | Nov 19, 2025 | Nov 18, 2025 |
| 10-Q | Quarterly report | Nov 13, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 13, 2025 | Nov 13, 2025 |
| 8-K |
Current report
Other events
|
Nov 3, 2025 | Nov 3, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 17, 2025 | Oct 17, 2025 |
| 4 | Insider transaction | Sep 4, 2025 | Sep 3, 2025 |
| 4 | Insider transaction | Sep 4, 2025 | Sep 3, 2025 |
| 4 | Insider transaction | Sep 4, 2025 | Sep 3, 2025 |
| 4 | Insider transaction | Sep 4, 2025 | Sep 3, 2025 |
| 4 | Insider transaction | Sep 4, 2025 | Sep 3, 2025 |
| 4 | Insider transaction | Sep 4, 2025 | Sep 3, 2025 |
| 4 | Insider transaction | Sep 4, 2025 | Sep 3, 2025 |
| 4 | Insider transaction | Sep 4, 2025 | Sep 3, 2025 |
| 4 | Insider transaction | Sep 4, 2025 | Sep 3, 2025 |
| 3 | Initial insider ownership | Aug 25, 2025 | Aug 24, 2025 |
| EFFECT | Filing | Aug 22, 2025 | — |
| 8-K |
Current report
Material agreement
|
Aug 22, 2025 | Aug 22, 2025 |
| 424B5 | Prospectus supplement | Aug 22, 2025 | — |
| CORRESP | Letter to the SEC | Aug 20, 2025 | — |
| S-3/A | Filing | Aug 14, 2025 | — |
| 10-Q | Quarterly report | Aug 14, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2025 | Aug 14, 2025 |
| 4 | Insider transaction | Aug 12, 2025 | Jun 10, 2025 |
| 8-K |
Current report
Other events
|
Aug 1, 2025 | Aug 1, 2025 |
| 8-K |
Current report
Material agreement, Officer or director change
|
Jul 21, 2025 | Jun 13, 2025 |
| 3 | Initial insider ownership | Jul 3, 2025 | Jun 26, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 26, 2025 | Jun 26, 2025 |
| 10-Q | Quarterly report | May 9, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 9, 2025 | May 9, 2025 |
| ARS | Annual report to shareholders | May 8, 2025 | Dec 31, 2024 |
| DEF 14A | Proxy statement | Apr 30, 2025 | Jun 26, 2025 |
| UPLOAD | Letter from the SEC | Apr 30, 2025 | — |
| S-3 | Shelf registration | Apr 28, 2025 | — |
| 8-K |
Current report
Officer or director change
|
Apr 23, 2025 | Apr 21, 2025 |
| 8-K |
Current report
Material agreement, Other events
|
Mar 17, 2025 | Mar 17, 2025 |
| 424B5 | Prospectus supplement | Mar 17, 2025 | — |
| 10-K | Annual report | Mar 17, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 17, 2025 | Mar 17, 2025 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Dec 31, 2024 | Dec 27, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 23, 2024 | Dec 23, 2024 |
| 10-Q | Quarterly report | Nov 14, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 14, 2024 | Nov 14, 2024 |
| 4/A | Filing | Nov 5, 2024 | Sep 23, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Oct 25, 2024 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 25, 2024 | Oct 25, 2024 |
| 4 | Insider transaction | Sep 24, 2024 | Sep 23, 2024 |
| 4 | Insider transaction | Sep 24, 2024 | Sep 23, 2024 |
| 10-Q | Quarterly report | Aug 14, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2024 | Aug 14, 2024 |
| S-8 | Employee stock plan registration | Jul 1, 2024 | — |
| 8-K |
Current report
Shareholder vote results
|
Jun 28, 2024 | Jun 27, 2024 |
| ARS | Annual report to shareholders | May 17, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | May 17, 2024 | — |
| 10-Q | Quarterly report | May 10, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Results of operations
|
May 10, 2024 | May 10, 2024 |
| DEF 14A | Proxy statement | Apr 29, 2024 | Jun 27, 2024 |
| 4 | Insider transaction | Apr 3, 2024 | Apr 1, 2023 |
| 10-K | Annual report | Mar 14, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 14, 2024 | Mar 14, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Jan 2, 2024 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 26, 2023 | Dec 26, 2023 |
| 10-Q | Quarterly report | Nov 6, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 6, 2023 | Nov 6, 2023 |
| 4 | Insider transaction | Oct 20, 2023 | Oct 19, 2023 |
| 4 | Insider transaction | Oct 3, 2023 | Sep 29, 2023 |
| 4 | Insider transaction | Oct 3, 2023 | Sep 29, 2023 |
| 4 | Insider transaction | Oct 3, 2023 | Sep 29, 2023 |
| 4 | Insider transaction | Oct 3, 2023 | Sep 29, 2023 |
| 4 | Insider transaction | Oct 3, 2023 | Sep 29, 2023 |
| 4 | Insider transaction | Sep 15, 2023 | Sep 14, 2023 |
| 3 | Initial insider ownership | Sep 15, 2023 | Sep 14, 2023 |
| 8-K |
Current report
Officer or director change
|
Sep 12, 2023 | Sep 12, 2023 |
| 4 | Insider transaction | Aug 17, 2023 | Aug 15, 2023 |
| 4 | Insider transaction | Aug 17, 2023 | Aug 15, 2023 |
| 4 | Insider transaction | Aug 17, 2023 | Aug 15, 2023 |
| 4 | Insider transaction | Aug 17, 2023 | Aug 15, 2023 |
| S-8 | Employee stock plan registration | Aug 11, 2023 | — |
| 10-Q | Quarterly report | Aug 7, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2023 | Aug 7, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jul 13, 2023 | Jul 13, 2023 |
| 424B3 | Prospectus | Jul 7, 2023 | — |
| 8-K |
Current report
Shareholder vote results
|
Jun 29, 2023 | Jun 28, 2023 |
| DEFA14A | Additional proxy material | Jun 28, 2023 | — |
| 8-K |
Current report
Regulation FD disclosure
|
May 30, 2023 | May 30, 2023 |
| ARS | Annual report to shareholders | May 19, 2023 | Dec 31, 2022 |
| DEF 14A | Proxy statement | May 18, 2023 | Jun 28, 2023 |
| 8-K |
Current report
Results of operations, Other events
|
May 18, 2023 | May 18, 2023 |
| 8-K |
Current report
Other events
|
May 10, 2023 | May 10, 2023 |
| 8-K |
Current report
Other events
|
May 5, 2023 | May 5, 2023 |
| 10-Q | Quarterly report | May 4, 2023 | Mar 31, 2023 |
| 8-K |
Current report
Results of operations
|
May 4, 2023 | May 4, 2023 |
| PRE 14A | Preliminary proxy statement | May 2, 2023 | May 2, 2023 |
| 10-K/A | Amended annual report | May 1, 2023 | Dec 31, 2022 |
| 424B5 | Prospectus supplement | Feb 27, 2023 | — |
| 8-K |
Current report
Material agreement, Other events
|
Feb 27, 2023 | Feb 27, 2023 |
| 10-K | Annual report | Feb 27, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Results of operations
|
Feb 27, 2023 | Feb 27, 2023 |
| 8-K |
Current report
Other events
|
Feb 24, 2023 | Feb 24, 2023 |
| 4 | Insider transaction | Jan 5, 2023 | Jan 3, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 3, 2023 | Jan 3, 2023 |
| SC 13G/A | Amended ownership over 5% (passive) | Jan 3, 2023 | — |
| 8-K |
Current report
Other events
|
Dec 27, 2022 | Dec 27, 2022 |
| 8-K |
Current report
Other events
|
Dec 21, 2022 | Dec 21, 2022 |
| 10-Q | Quarterly report | Nov 14, 2022 | Sep 30, 2022 |
| 8-K |
Current report
Results of operations, Other events
|
Nov 14, 2022 | Nov 9, 2022 |
| 4 | Insider transaction | Sep 9, 2022 | Sep 7, 2022 |
| 4 | Insider transaction | Sep 9, 2022 | Sep 7, 2022 |
| 4 | Insider transaction | Sep 9, 2022 | Sep 7, 2022 |
| 4 | Insider transaction | Sep 9, 2022 | Sep 7, 2022 |
| 4 | Insider transaction | Sep 9, 2022 | Sep 7, 2022 |
| 4 | Insider transaction | Sep 9, 2022 | Sep 7, 2022 |
| 4 | Insider transaction | Sep 9, 2022 | Sep 7, 2022 |
| 4 | Insider transaction | Sep 9, 2022 | Sep 7, 2022 |
| 4 | Insider transaction | Sep 9, 2022 | Sep 7, 2022 |
| 4 | Insider transaction | Sep 9, 2022 | Sep 7, 2022 |
| 8-K |
Current report
Material agreement
|
Sep 1, 2022 | Aug 29, 2022 |
| 10-Q | Quarterly report | Aug 15, 2022 | Jun 30, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 15, 2022 | Aug 15, 2022 |
| S-8 | Employee stock plan registration | Jul 14, 2022 | — |
| 4 | Insider transaction | Jul 5, 2022 | Jun 30, 2022 |
| 3 | Initial insider ownership | Jul 5, 2022 | Jun 30, 2022 |
| 8-K |
Current report
Officer or director change, Shareholder vote results, Other events
|
Jun 30, 2022 | Jun 29, 2022 |
| UPLOAD | Letter from the SEC | Jun 30, 2022 | — |
| CORRESP | Letter to the SEC | Jun 29, 2022 | — |
| UPLOAD | Letter from the SEC | Jun 23, 2022 | — |
| DEFA14A | Additional proxy material | Jun 16, 2022 | — |
| SC 13G | Ownership over 5% (passive) | Jun 9, 2022 | — |
| 8-K |
Current report
Regulation FD disclosure
|
May 26, 2022 | May 26, 2022 |
| 10-Q | Quarterly report | May 16, 2022 | Mar 31, 2022 |
| 8-K |
Current report
Results of operations
|
May 16, 2022 | May 16, 2022 |
| 8-K |
Current report
Material agreement
|
May 2, 2022 | May 2, 2022 |
| 424B5 | Prospectus supplement | May 2, 2022 | — |
| EFFECT | Filing | Apr 29, 2022 | — |
| DEF 14A | Proxy statement | Apr 29, 2022 | Jun 30, 2022 |
| CORRESP | Letter to the SEC | Apr 27, 2022 | — |
| UPLOAD | Letter from the SEC | Apr 25, 2022 | — |
| S-3 | Shelf registration | Apr 20, 2022 | — |
| PRE 14A | Preliminary proxy statement | Apr 14, 2022 | Apr 14, 2022 |
| 4 | Insider transaction | Apr 13, 2022 | Apr 11, 2022 |
| 8-K |
Current report
Other events
|
Apr 4, 2022 | Apr 4, 2022 |
| 10-K | Annual report | Mar 31, 2022 | Dec 31, 2021 |
| 8-K |
Current report
Results of operations
|
Mar 31, 2022 | Mar 31, 2022 |
| 4 | Insider transaction | Feb 28, 2022 | Feb 25, 2022 |
| 4 | Insider transaction | Feb 28, 2022 | Feb 25, 2022 |
| 8-K |
Current report
Other events
|
Feb 24, 2022 | Feb 24, 2022 |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2022 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 11, 2022 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Jan 31, 2022 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 22, 2021 | Dec 22, 2021 |
| 8-K |
Current report
Shareholder vote results
|
Nov 24, 2021 | Nov 24, 2021 |
| 10-Q | Quarterly report | Nov 15, 2021 | Sep 30, 2021 |
| 8-K |
Current report
Results of operations
|
Nov 15, 2021 | Nov 15, 2021 |
| DEFA14A | Additional proxy material | Nov 9, 2021 | — |
| 8-K |
Current report
Other events
|
Oct 12, 2021 | Oct 11, 2021 |
| DEF 14A | Proxy statement | Sep 30, 2021 | Nov 24, 2021 |
| PRE 14A | Preliminary proxy statement | Sep 17, 2021 | Nov 24, 2021 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Aug 26, 2021 | Aug 24, 2021 |
| 10-Q | Quarterly report | Aug 16, 2021 | Jun 30, 2021 |
| 8-K |
Current report
Results of operations
|
Aug 16, 2021 | Aug 16, 2021 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Other events
|
Aug 13, 2021 | Aug 12, 2021 |
| SC 13G/A | Amended ownership over 5% (passive) | Jul 30, 2021 | — |
| 8-K |
Current report
Shareholder vote results
|
Jul 7, 2021 | Jul 7, 2021 |
| 424B5 | Prospectus supplement | Jul 2, 2021 | — |
| 8-K |
Current report
Material agreement, Agreement ended, Other events
|
Jul 2, 2021 | Jul 2, 2021 |
| 424B5 | Prospectus supplement | Jul 2, 2021 | — |
| 8-K |
Current report
Other events
|
Jun 30, 2021 | Jun 30, 2021 |
| SC 13G/A | Amended ownership over 5% (passive) | Jun 15, 2021 | — |
| DEF 14A | Proxy statement | Jun 4, 2021 | Jul 7, 2021 |
| 4 | Insider transaction | Jun 3, 2021 | Jun 2, 2021 |
| 8-K |
Current report
Other events
|
Jun 2, 2021 | Jun 2, 2021 |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- PLX (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Hackensack, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1006281
- Former names
- ORTHODONTIX INC (until Feb 22, 2007); EMBASSY ACQUISITION CORP (until Mar 31, 1998)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.